Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects
Diabetes mellitus (DM) is a metabolic disorder that leads to the destruction of various tissues including bones. The pathogenesis of osteoporosis (OP) varies in DM due to many specific factors. DM increases the risk of fracture as well as post-fracture mortality. It is because of this fact that OP t...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Indian Journal of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ijem.ijem_81_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850225408099745792 |
|---|---|
| author | Harsh Durgia Rajan Palui Jayaprakash Sahoo Sadishkumar Kamalanathan Dukhabandhu Naik |
| author_facet | Harsh Durgia Rajan Palui Jayaprakash Sahoo Sadishkumar Kamalanathan Dukhabandhu Naik |
| author_sort | Harsh Durgia |
| collection | DOAJ |
| description | Diabetes mellitus (DM) is a metabolic disorder that leads to the destruction of various tissues including bones. The pathogenesis of osteoporosis (OP) varies in DM due to many specific factors. DM increases the risk of fracture as well as post-fracture mortality. It is because of this fact that OP treatment should not be neglected in patients with DM. OP therapy comprises anabolic as well as anti-resorptive agents. Primary OP as observed in post-menopausal women is associated with high bone turnover, whereas OP in DM is a disease of low bone turnover. Therefore, anabolic agents seem to be quite promising in cases of OP in DM. Although the anti-fracture efficacy of these drugs is proven beyond any doubt in the general population without DM, evidence in persons with DM is limited. Among the anabolic agents, teriparatide has the most evidence in favor of its efficacy and safety in persons with DM. Studies evaluating other anabolic agents such as abaloparatide and romosozumab in diabetic osteopathy are scarce in the literature. Future studies specifically in both type 1 and type 2 DM populations are needed to evaluate the effects of osteoanabolic agents. |
| format | Article |
| id | doaj-art-0b90de02158e406aa56741fcb4637a40 |
| institution | OA Journals |
| issn | 2230-8210 2230-9500 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Endocrinology and Metabolism |
| spelling | doaj-art-0b90de02158e406aa56741fcb4637a402025-08-20T02:05:21ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102230-95002025-01-01291323810.4103/ijem.ijem_81_24Role of Anabolic Anti-Osteoporosis Therapy in Diabetes SubjectsHarsh DurgiaRajan PaluiJayaprakash SahooSadishkumar KamalanathanDukhabandhu NaikDiabetes mellitus (DM) is a metabolic disorder that leads to the destruction of various tissues including bones. The pathogenesis of osteoporosis (OP) varies in DM due to many specific factors. DM increases the risk of fracture as well as post-fracture mortality. It is because of this fact that OP treatment should not be neglected in patients with DM. OP therapy comprises anabolic as well as anti-resorptive agents. Primary OP as observed in post-menopausal women is associated with high bone turnover, whereas OP in DM is a disease of low bone turnover. Therefore, anabolic agents seem to be quite promising in cases of OP in DM. Although the anti-fracture efficacy of these drugs is proven beyond any doubt in the general population without DM, evidence in persons with DM is limited. Among the anabolic agents, teriparatide has the most evidence in favor of its efficacy and safety in persons with DM. Studies evaluating other anabolic agents such as abaloparatide and romosozumab in diabetic osteopathy are scarce in the literature. Future studies specifically in both type 1 and type 2 DM populations are needed to evaluate the effects of osteoanabolic agents.https://journals.lww.com/10.4103/ijem.ijem_81_24abaloparatideanabolicdiabetes mellitusosteoporosisromosozumabteriparatide |
| spellingShingle | Harsh Durgia Rajan Palui Jayaprakash Sahoo Sadishkumar Kamalanathan Dukhabandhu Naik Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects Indian Journal of Endocrinology and Metabolism abaloparatide anabolic diabetes mellitus osteoporosis romosozumab teriparatide |
| title | Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects |
| title_full | Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects |
| title_fullStr | Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects |
| title_full_unstemmed | Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects |
| title_short | Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects |
| title_sort | role of anabolic anti osteoporosis therapy in diabetes subjects |
| topic | abaloparatide anabolic diabetes mellitus osteoporosis romosozumab teriparatide |
| url | https://journals.lww.com/10.4103/ijem.ijem_81_24 |
| work_keys_str_mv | AT harshdurgia roleofanabolicantiosteoporosistherapyindiabetessubjects AT rajanpalui roleofanabolicantiosteoporosistherapyindiabetessubjects AT jayaprakashsahoo roleofanabolicantiosteoporosistherapyindiabetessubjects AT sadishkumarkamalanathan roleofanabolicantiosteoporosistherapyindiabetessubjects AT dukhabandhunaik roleofanabolicantiosteoporosistherapyindiabetessubjects |